Mayne Pharma USA Names New President
Mayne Pharma Group Limited has named Stefan Cross as president of Mayne Pharma USA.
Cross is responsible for leading all of Mayne Pharma’s existing business operations in the United States, and for spearheading new business development initiatives.
Among those responsibilities includes managing the continued growth of contract pharmaceutical services as provided by Mayne Pharma’s subsidiary, Metrics Inc., and positioning it to become one of North America’s leading providers of solid oral dose formulation development and analytical support services. To that end, the company plans to make significant investments in Metrics’ fast-track, proof-of-concept, and first-time-in-man programs, potent and cytotoxic product handling, and clinical trial material manufacturing for contract services clients.
Cross also will oversee the expansion of Mayne Pharma USA’s pharmaceutical products division, which has been one of the fastest-growing U.S. generics businesses in recent years. This business – established less than 10 years ago – now markets more than 20 products and has 20 products under development with 10 ANDAs filed with the FDA. Cross will focus on expanding the U.S. product portfolio through both organic development and further bolt-on acquisitions.
Prior to this most recent promotion, Cross served as Mayne Pharma’s vice president of business and corporate development, and played a key role in the global commercialization of the company’s SUBACAP® anti-fungal product. He has been extensively involved in integrating Metrics with Mayne Pharma, and in executing the company’s business strategy in Australia and the United States since joining in 2012.
Cross brings more than 20 years of industry experience to his role. He previously headed marketing efforts in the Asia Pacific region for Hospira Inc., a leading global provider of pharmaceuticals and medical devices. He also led Hospira’s commercial operations in China, Hong Kong and Taiwan. Prior to that, Cross worked for six years with Mayne Pharma Limited in Europe and Australia, and eight years with F.H. Faulding & Co. Limited.
“Stefan has an impressive track record of success in the pharmaceutical industry and will add tremendous value to our U.S. business,” said Scott Richards, CEO of Mayne Pharma. “His breadth of experience covers commercial operations, marketing, product licensing, business strategy and M&A. I look forward to accelerating the growth of our U.S. businesses with Stefan’s support and leadership.”
Cross succeeds Phil Hodges, who founded Metrics Inc. almost two decades ago and recently retired as president of the company. Hodges serves on the board of directors of Mayne Pharma Group Limited.